FDA feedback backs Noxopharm’s SOF-SKN Phase II plan
Noxopharm (ASX:NOX) has received constructive feedback from the US Food & Drug Administration (FDA) that was supportive of its planned Phase II clinical trial approach for SOF-SKN™, the company’s autoimmune disease drug candidate. The update was released on 8 October 2026.
The feedback follows Noxopharm’s 7 July 2026 announcement, when the company formally requested a pre-Investigational New Drug (IND) meeting with the FDA. According to the company, the feedback provides increased regulatory clarity and helps de-risk SOF-SKN’s development pathway.
Dr Olivier Laczka, Noxopharm CEO
“Engagement with the FDA at this stage is a critical step in our progress along the clinical trials pathway…”
The headline takeaways from the announcement are:
- The FDA was supportive of Noxopharm’s planned approach
- The Phase II trial is targeted for H1 CY28, subject to regulatory, clinical and manufacturing requirements
- An Orphan Drug Designation opportunity exists for SOF-SKN
What the FDA said
Through the pre-IND meeting process, the FDA formally provided its views on the planned clinical development pathway. Topics covered included clinical trial design, product manufacturing, non-clinical safety studies, and other requirements to support a comprehensive IND application.
At a high level, the FDA’s views were as follows:
- It was supportive of Noxopharm’s approach and of the company’s proposal on how this novel technology could fit into the agency’s regulatory framework.
- The feedback was particularly supportive of the chemical manufacturing strategy.
- The agency considered the proposed Phase II trial design as reasonable.
- It provided technical guidance to ensure alignment with its expectations around the proposed non-clinical studies.
This is feedback only, not FDA approval or clearance. Manufacturing and trial design are common sources of regulatory delay, so early alignment on both may lower uncertainty for the program ahead.
When big ASX news breaks, our subscribers know first
Understanding the pre-IND process and why it matters
A pre-IND meeting is an early consultation with the FDA before a formal IND submission. An IND is required to begin clinical trials in the US.
For investors, the practical value is that Noxopharm can incorporate the FDA’s feedback into a planned series of substantive and highly relevant technical studies leading up to the trial. The company described this early engagement as an important de-risking process.
Progressing through the IND process could increase SOF-SKN’s commercial potential and make the drug more attractive to industry in the US and elsewhere. The announcement states that Noxopharm will also prepare for a future IND submission to support potential US clinical development.
The outcome follows several years of extensive strategic, research and preparatory work with industry-leading regulatory experts on how the company would develop and present its novel Sofra™ technology platform to the FDA. The learnings may also help inform future regulatory planning for other Sofra-derived assets.
Next steps and market opportunity
Roadmap and timeline
The announcement outlines the following milestones. No dates were disclosed for the extension study or the IND submission.
The Melbourne extension is a 15-patient CLE study built around 14 days of daily topical dosing, with initial efficacy signals targeted for Q2 CY27 and a full data readout for Q4 CY27.
| Milestone | Status/Timing | Investor significance |
|---|---|---|
| Pre-IND feedback | Received | Increased regulatory clarity on the development pathway |
| Extension study in cutaneous lupus erythematosus (CLE) patients in Melbourne | Final preparations | Continues clinical development after Phase I completion |
| Future IND submission | In preparation | Could increase SOF-SKN’s commercial potential |
| Phase II trial | Targeted for H1 CY28, subject to regulatory, clinical and manufacturing requirements | Next major clinical stage for SOF-SKN |
The CLE opportunity
Lupus is an autoimmune disease that can affect different organs, and CLE is a sub-type that manifests in the skin. There are currently no therapies specifically approved for treating CLE, and the company describes a significant unmet need for targeted and well-tolerated therapies.
SOF-SKN also represents a potential Orphan Drug Designation opportunity. The announcement states the global market was valued at US$5.4 billion in 2024.
The Sofra platform is based on synthetic nucleic acids, known as oligonucleotides, which mimic natural regulators of the body’s defence system. The global autoimmune disease therapeutics market was worth US$163.2 billion in 2024 and is expected to reach US$219.6 billion by 2035.
Phase I has been completed, the extension study is in final preparations, and Noxopharm will prepare for a future IND submission to support potential US clinical development.
Get Biotech News Before the Market Moves
Big News Blast delivers FREE breaking ASX biotech and healthcare news to your inbox within minutes of release, complete with in-depth analysis and the full announcement. Join 20,000+ subscribers by clicking the “Free Alerts” button at Big News Blast and stay ahead the moment news breaks.